Palmitoyl Dipeptide-6 Limited Evidence

What It Is

Palmitoyl Dipeptide-6 is the INCI (International Nomenclature of Cosmetic Ingredients) name for a family of two-amino-acid peptides conjugated at the N-terminus to a 16-carbon palmitic acid tail and sold as cosmetic actives. The most frequently cited sequence is palmitoyl-Val-Trp (pal-VW), a short hydrophobic dipeptide whose palmitoylation produces an amphiphilic lipopeptide with improved affinity for the lipid matrix of the stratum corneum. Related supplier-branded materials under the INCI "Palmitoyl Dipeptide-6 Diaminohydroxybutyrate" (a different chemical entity used in products such as Sederma's Syn-Tacks and Syn-Ake-adjacent blends) share the "Palmitoyl Dipeptide-6" prefix but are chemically distinct and frequently confused with the plain pal-Val-Trp material. Readers should verify supplier datasheets for the exact structure of any material labeled "Palmitoyl Dipeptide-6" in a finished product.

The broader class — palmitoylated cosmetic peptides — was established commercially in the late 1990s and early 2000s when Sederma introduced Matrixyl (palmitoyl pentapeptide-3, later renamed palmitoyl pentapeptide-4 in 2006, sequence palmitoyl-KTTKS) as a topical analog of a pro-collagen I carboxy-terminal fragment first shown to stimulate fibroblast ECM production by Katayama and colleagues in 1993 (PMID 8486721). The strategic logic was explicit: take a short, biologically interesting peptide sequence; attach a palmitic acid chain to overcome stratum-corneum exclusion of polar low-molecular-weight peptides; formulate into a topical vehicle; and market the ingredient to finished-product brands as a "signal peptide" that engages fibroblasts to produce more collagen, elastin, and fibronectin. Palmitoyl Dipeptide-6 belongs to this same strategic family — it is shorter (two amino acids rather than five) and is marketed by multiple cosmetic peptide suppliers as a skin-firming active, typically at inclusion levels of 1–4% in finished formulations.

Unlike Matrixyl, for which the underlying pentapeptide KTTKS has decades of fibroblast-ECM in vitro data, Palmitoyl Dipeptide-6 (pal-VW) does not have a comparable body of independent biochemistry behind it. Valine-tryptophan is not a canonical matrikine motif recognized in the peer-reviewed dermatological literature; supplier dossiers cite internal in-vitro experiments (proprietary fibroblast assays, gene-expression panels, ex-vivo skin explant measurements) to substantiate mechanism claims. In practice, the pal-VW active is marketed on the twin pillars of (1) the palmitoylation delivery story that applies to the entire cosmetic-lipopeptide class and (2) generic signal-peptide language extrapolated from Matrixyl, Rigin, and copper peptide literature.

The supplier landscape is fragmented. Palmitoyl Dipeptide-6 (and the distinct Palmitoyl Dipeptide-6 Diaminohydroxybutyrate material) is produced by several cosmetic peptide manufacturers including Sederma (a Croda company), DSM/Pentapharm, Lipotec/Lubrizol adjacent suppliers, and multiple Asian peptide-synthesis houses that supply ingredient-level material to finished-product brands. No single manufacturer owns the INCI exclusively. This differs sharply from branded actives like Argireline (acetyl hexapeptide-8, Lubrizol) or Matrixyl (Sederma) where a single supplier controls the narrative and publishes the sponsored in-vivo supporting data. The diffuse supplier landscape for Palmitoyl Dipeptide-6 partly explains the thin published record — no single party has had the commercial incentive to fund, execute, and publish a peer-reviewed RCT on a finished product whose primary claim hinges on this specific INCI.

Mechanism of Action

Palmitoyl Dipeptide-6's mechanism claims are drawn from the general pharmacology of cosmetic lipopeptides plus supplier-dossier in-vitro data. Readers should treat the specificity of each mechanistic claim as proportional to the supporting evidence — which here is primarily class-level inference rather than compound-specific peer-reviewed demonstration.

• Palmitoyl delivery strategy (class-level, mechanistically robust) — Attachment of a C16 palmitic-acid tail converts a polar short peptide into an amphiphile that partitions into stratum-corneum lipids rather than being excluded from them. Molecular dynamics simulations and ex-vivo skin-permeation studies of pal-KTTKS, pal-GHK, and palmitoyl-carnosine consistently show the palmitoyl tail inserts into stratum-corneum lipid bilayers, increasing residence time in the skin barrier and slowing clearance into the systemic circulation (Castelletto et al., 2013; Abu Samah & Heard, PMID 21535443). For Palmitoyl Dipeptide-6 specifically, the palmitoylation strategy is the most mechanistically defensible claim — the same lipid-anchoring physics that applies to the entire lipopeptide class applies to pal-VW.
• Claimed fibroblast stimulation (supplier-dossier) — Marketing documents from cosmetic peptide suppliers cite in-vitro fibroblast assays in which Palmitoyl Dipeptide-6 is reported to increase expression of extracellular-matrix genes (procollagen I, procollagen III, fibronectin, elastin). These assays are proprietary, not peer-reviewed, and typically run at peptide concentrations many-fold higher than what reaches fibroblasts through intact human stratum corneum in vivo. The gap between in-vitro concentration-response curves and in-vivo skin bioavailability is the single largest weakness in the cosmetic-peptide mechanism literature as a whole, and Palmitoyl Dipeptide-6 is no exception.
• Claimed ECM / matrix-supportive signaling — Supplier literature positions Palmitoyl Dipeptide-6 as engaging TGF-β pathway signaling and integrin-associated matrix remodeling. These are plausible effector pathways for any signal peptide that influences fibroblast phenotype, but the specific evidence that pal-VW engages TGF-β receptors or modulates SMAD-family transcription factors in human dermal fibroblasts has not been independently published at the time of this profile.
• Theoretical procollagen messaging — By analogy to KTTKS (a subfragment of the C-terminal propeptide of type I procollagen demonstrated in Katayama 1993 to feedback-stimulate collagen synthesis), supplier narratives position short peptide fragments as "matrikines" capable of mimicking endogenous procollagen-derived messengers. Valine-tryptophan is not a published procollagen-derived matrikine, so this framing is a conceptual appeal rather than a mechanism demonstrated for pal-VW specifically.
• Comparison with Matrixyl (palmitoyl pentapeptide-4, pal-KTTKS) — Matrixyl has at minimum Robinson et al. 2005 (PMID 18492182) as a 12-week split-face RCT in 93 women showing fine-line reduction at 3 ppm pal-KTTKS versus moisturizer control. Palmitoyl Dipeptide-6 has no comparable independent clinical trial. Mechanistically, both rely on the same palmitoyl-delivery strategy; clinically, Matrixyl's evidence base is weak but exists, whereas Palmitoyl Dipeptide-6's is essentially absent from the peer-reviewed literature.
• Comparison with Argireline (acetyl hexapeptide-8) — A fundamentally different mechanism class (SNAP-25 N-terminal mimetic, blocking SNARE complex assembly and acetylcholine exocytosis). Argireline at least has a published mechanism paper (Blanes-Mira 2002) and multiple small topical clinical trials. Palmitoyl Dipeptide-6 does not claim neuromuscular modulation — it sits in the signal-peptide category, not the neurotransmitter-affecting category.
• Comparison with Copper GHK-Cu — GHK-Cu (and palmitoylated pal-GHK) has a substantial independent published literature including Pickart's original 1973 identification, gene-expression microarray studies, and wound-healing models. Palmitoyl Dipeptide-6 shares the general "signal peptide" framing but does not share GHK-Cu's depth of mechanistic characterization.
• Self-assembly behavior — Palmitoyl lipopeptides (including pal-KTTKS, pal-GHK, pal-KT) are amphiphilic molecules that self-assemble into nanotape or micellar structures above a critical aggregation concentration (Castelletto et al., Langmuir 2013). Whether this self-assembly is mechanistically relevant to cosmetic efficacy, or simply a physical behavior incidental to the palmitoylation strategy, remains unresolved in the academic literature. Palmitoyl Dipeptide-6 almost certainly shares this self-assembly behavior given its structure; the functional consequences in formulation are not established.
• TGF-β speculation — The supplier framing that Palmitoyl Dipeptide-6 modulates TGF-β signaling to support ECM deposition is plausible by analogy to the broader signal-peptide class. It is not a claim that has been independently validated in human skin biopsy samples or blinded gene-expression analysis. Readers should weigh this as a hypothesis rather than an established mechanism.
• Not a neurotransmitter-affecting peptide — Palmitoyl Dipeptide-6 is not a "botox-like" peptide. It does not target SNAP-25, SNARE complex, acetylcholine release, or any neuromuscular pathway. Any marketing that implies Palmitoyl Dipeptide-6 relaxes expression lines by a mechanism similar to botulinum toxin is reaching beyond the supplier-dossier data.

What the Research Shows

The honest summary: almost nothing. Palmitoyl Dipeptide-6 does not have a peer-reviewed clinical research base of its own. The evidence that exists is drawn from the broader cosmetic lipopeptide category, from supplier marketing dossiers, and from mechanistic inference — none of which is a substitute for an independent randomized controlled trial of a finished product.

• No published finished-product RCT — A PubMed search in April 2026 for clinical trials in which Palmitoyl Dipeptide-6 is the primary active returns no independent peer-reviewed randomized controlled trial. This is in contrast to Matrixyl (Robinson 2005, PMID 18492182), Argireline (Blanes-Mira 2002 and subsequent small trials), and copper peptides (multiple in-vivo studies) — each of which has at least one real published clinical paper, however methodologically limited.
• Category-level support from Matrixyl (pal-KTTKS) — Robinson et al. 2005 (PMID 18492182) enrolled 93 Caucasian women aged 35–55 in a 12-week split-face double-blind placebo-controlled trial. Moisturizer with 3 ppm pal-KTTKS produced statistically significant reduction in fine lines and wrinkles versus moisturizer control by both quantitative image analysis and expert-grader assessment. This trial does not speak to Palmitoyl Dipeptide-6 efficacy directly — it speaks only to the broader palmitoyl-lipopeptide-in-moisturizer delivery strategy at low parts-per-million inclusion levels.
• KTTKS in-vitro substrate — Katayama et al. 1993 (PMID 8486721) demonstrated that the KTTKS pentapeptide (a subfragment of the type I procollagen C-terminal propeptide) promoted type I collagen, type III collagen, and fibronectin production in cultured fibroblasts in a dose- and time-dependent manner without affecting total protein synthesis. This is the founding biochemistry of the matrikine concept for cosmetic signal peptides. It is the mechanism literature for KTTKS, not for Val-Trp, and should not be invoked as evidence for Palmitoyl Dipeptide-6.
• Palmitoylation-enhances-permeation literature — Molecular dynamics and ex-vivo skin-permeation work (for example Hamley and collaborators on palmitoyl lipopeptide self-assembly, and the Cardiff group's review of topically applied KTTKS, PMID 21535443) supports the class-level claim that palmitoylation improves stratum-corneum permeation of short polar peptides. Again, this is class-level support — it tells you pal-VW probably does reach the viable epidermis more effectively than unmodified VW, but it does not tell you that VW or pal-VW exerts any clinically meaningful effect once there.
• Argireline precedent — Blanes-Mira et al. 2002 established acetyl hexapeptide-3 (now acetyl hexapeptide-8) as a topical SNAP-25 mimetic in a proof-of-concept cosmetic-ingredient paper. Subsequent small trials (reviewed in PMID 23146065 for blepharospasm, and in multiple small efficacy studies summarized in the 2025 PMC12193160 review) demonstrate that a cosmetic peptide active with a clearly defined molecular mechanism can accrue a modest but real clinical literature. Palmitoyl Dipeptide-6 has not yet accrued anything comparable.
• Cosmeceutical peptide reviews — Lupo & Cole 2007 (PMID 18045359) and Schagen 2017 (MDPI Cosmetics 4(2):16) survey the cosmetic peptide field and classify palmitoyl lipopeptides as "signal peptides" with modest but real topical evidence for the leading members of the class. Neither review identifies Palmitoyl Dipeptide-6 as an ingredient with independent clinical substantiation — both mention it, if at all, as part of the broader lipopeptide category.
• Sensitive-skin usage analysis — A 2021 analysis of 88 facial cosmetic products for sensitive skin found that palmitoyl tripeptide-5, palmitoyl tetrapeptide-7, and palmitoyl oligopeptide appeared in at least one product each; Palmitoyl Dipeptide-6 was not among the most-used peptides identified in that survey, consistent with its lower market penetration relative to Matrixyl-family actives and Argireline.
• Oral collagen peptide literature is not relevant — Proksch 2014 (PMID 23949208) and the broader oral collagen peptide RCT literature address gastrointestinal-absorbed collagen hydrolysate, which bears no mechanistic relationship to a topical lipopeptide like Palmitoyl Dipeptide-6. It is cited here only to flag a common conflation: being a "peptide" does not make oral collagen peptide evidence transferable to topical lipopeptide marketing claims.
• CIR safety assessment — The Cosmetic Ingredient Review Expert Panel safety assessment of palmitoyl oligopeptides (CIR 2012) concluded the class is safe as used in cosmetics. This is a class-level safety assessment covering multiple INCI entries; it substantiates safety, not efficacy. For Palmitoyl Dipeptide-6, CIR-level safety documentation is the single most substantive regulatory-grade data point in the public record.

Human Data

Be direct: there is essentially no peer-reviewed human clinical trial data specific to Palmitoyl Dipeptide-6. PubMed, ClinicalTrials.gov, and EU Clinical Trials Register do not list a completed randomized controlled trial of a topical finished product in which Palmitoyl Dipeptide-6 is the named primary active. The following paragraphs describe the category human data (relevant to the palmitoyl-lipopeptide class as a whole) and the manufacturer-dossier human data (proprietary, not peer-reviewed, not independently verifiable).

• Matrixyl pivotal trial (PMID 18492182) — Robinson 2005. 93 Caucasian women, aged 35–55, 12-week split-face double-blind placebo-controlled design. Moisturizer with 3 ppm pal-KTTKS vs. same moisturizer without pal-KTTKS. Primary endpoints: fine-line density, wrinkle depth by quantitative image analysis, expert-grader rating. Result: statistically significant wrinkle reduction in the pal-KTTKS arm. This is the strongest finished-product evidence in the palmitoyl-lipopeptide class.
• KTTKS fibroblast biochemistry (PMID 8486721) — Katayama 1993. The foundational in-vitro demonstration that the pentapeptide KTTKS (a procollagen I C-terminal propeptide fragment) increases collagen I, collagen III, and fibronectin production in fibroblast cultures. Not human in-vivo data, but the mechanistic anchor for the entire signal-peptide cosmetic-ingredient category.
• Acetyl hexapeptide-8 topical blepharospasm trial (PMID 23146065) — Small 2012 pilot in patients receiving botulinum neurotoxin for blepharospasm, testing topical acetyl hexapeptide-8 as an adjunct. Demonstrated proof-of-concept that a topical cosmetic peptide with a defined molecular mechanism can reach clinically relevant tissue in periocular skin. Tangentially relevant for cosmetic signal-peptide category framing; not directly relevant to Palmitoyl Dipeptide-6.
• Topically applied KTTKS review (PMID 21535443) — Abu Samah and Heard 2011. Comprehensive review of KTTKS and its major derivatives (including pal-KTTKS Matrixyl) covering physicochemical properties, theoretical skin permeation, and published evidence. Useful for understanding the class-level pharmacokinetic rationale for lipopeptide cosmetic actives.
• Biologically active peptides cosmetic review (PMID 18503476) — Lintner & Peschard 2000. The foundational review paper from Sederma's chief researcher establishing the cosmetic-peptide conceptual framework. Describes the palmitoylation strategy, matrikine concept, and chemotaxis / anti-stinging effects. Not Palmitoyl Dipeptide-6-specific but establishes the supplier-dossier vocabulary that pal-VW marketing inherits.
• Cosmeceutical peptides dermatologic review (PMID 18045359) — Lupo & Cole 2007. Three-category classification (signal, neurotransmitter-affecting, carrier) of cosmetic peptides. Notes the limited rigor of efficacy testing for the class as a whole — a theme that applies acutely to Palmitoyl Dipeptide-6.
• Oral collagen peptide RCT (PMID 23949208) — Proksch 2014. Oral hydrolyzed collagen peptide randomized trial. Cited here solely to clarify that oral collagen peptide evidence is not transferable to topical lipopeptide efficacy claims; consumers and marketing copy frequently conflate these literatures.
• Manufacturer dossier-level human data — Multiple cosmetic peptide suppliers (Sederma, DSM/Pentapharm, Lipotec, and smaller Asian suppliers) maintain internal panel-test and consumer-perception data on Palmitoyl Dipeptide-6 and related lipopeptide actives. These are not peer-reviewed, typically involve small single-arm consumer panels (n = 20–40), and report self-reported skin-feel improvement rather than objective endpoints. They do not constitute clinical evidence in the sense required by drug regulatory authorities, and should not be confused with RCT data.
• Post-market pharmacovigilance — Palmitoyl Dipeptide-6 has been in cosmetic use at modest scale for approximately 15 years without surfacing meaningful safety signals in CIR reports, EU CosIng entries, or FDA adverse-event databases. Absence of harm is not evidence of benefit but is the relevant safety framing for a cosmetic ingredient that has not produced independent efficacy data.
• ClinicalTrials.gov search (April 2026) — No registered prospective clinical trial for Palmitoyl Dipeptide-6 as intervention or as component of the primary intervention product. Contrast: Matrixyl and acetyl hexapeptide-8 each have multiple registrations, though quality and completion rates are mixed.

The bottom line for human data: Palmitoyl Dipeptide-6 is a cosmetic ingredient supported by safety documentation and mechanistic plausibility within the lipopeptide class, not by independent efficacy trials. Any product marketing that cites "clinical studies prove" should be scrutinized for whether those studies are peer-reviewed, whether they are on the finished product versus an isolated active, and whether the primary active being evaluated is Palmitoyl Dipeptide-6 or a different peptide that is piggybacking on broader category data.

Dosing from the Literature

Palmitoyl Dipeptide-6 is a cosmetic topical ingredient used at formulation-level inclusion percentages. There is no "dose" in the pharmacological sense — efficacy and safety are established (or, in this case, not established) at formulation-level concentrations across a typical twice-daily application regimen. Supplier technical dossiers recommend inclusion levels as follows:

The inclusion percentages above reflect supplier dossier recommendations. They should not be read as dose-response-validated figures — there is no published dose-response curve for Palmitoyl Dipeptide-6 in human skin, so the "optimal" concentration is unknown. For comparison, Matrixyl (pal-KTTKS) is typically formulated at 3–8 ppm (0.0003–0.0008%) in finished products and showed efficacy in Robinson 2005 at 3 ppm — a concentration roughly 1,000-fold lower than the typical Palmitoyl Dipeptide-6 inclusion level. This concentration mismatch is not evidence that Palmitoyl Dipeptide-6 requires higher concentration for efficacy; it simply reflects that the two ingredients are not pharmacologically equivalent and their marketing-recommended use levels emerge from different commercial and formulation considerations.

Reconstitution & Storage

Palmitoyl Dipeptide-6 is supplied to formulators as either a solid powder or a pre-solubilized stock concentrate in a glycol or lipid carrier. It is not a clinic-reconstituted injectable. Formulator-level handling guidance for the ingredient is summarized below; this is not consumer-level guidance.

• Formulation pH — Best stability in the mildly acidic-to-neutral range (pH 5–7). Strongly alkaline systems accelerate peptide-bond hydrolysis; strongly acidic systems can protonate the tryptophan indole and risk side-chain oxidation during processing.
• Antioxidant load — Tryptophan is one of the most oxidation-prone amino acids. Finished formulations should carry a meaningful antioxidant system (tocopherol 0.1–0.5%, or equivalent) to protect the dipeptide from color-shift and activity loss during shelf life.
• Emulsion compatibility — Compatible with most nonionic and anionic emulsifiers used in skincare. Cationic emulsifiers can form ion pairs with the tryptophan indole and reduce bioavailability in-vehicle; avoid or validate stability data before use.
• Storage (raw material) — Sealed containers at cool ambient temperature (below 25°C), protected from light, away from humidity. Refrigeration is acceptable but not required; freezing is not recommended for glycol-based stock concentrates because recovery from freeze-thaw cycles can produce turbidity.
• Storage (finished product) — Most palmitoyl-lipopeptide cosmetic products are designed for 24–36 month ambient shelf life. Consumers should store away from direct sunlight and heat, recap tightly, and use within 6–12 months of first opening to minimize oxidation.
• Incompatibilities — Avoid combining with high concentrations of retinoid-activating acids in the same phase during processing (retinol is separately sensitive and should share antioxidant protection but may be combined in final formulations with proper stabilization). Avoid combining with strong oxidants or elevated-concentration hydroxyl-radical-generating systems.
• No injectable reconstitution — Palmitoyl Dipeptide-6 has no pharmaceutical-grade injectable specification. It is not approved, tested, or manufactured for parenteral use. Any vendor suggesting reconstitution with bacteriostatic water for injection is misusing the cosmetic ingredient.

→ Use the Kalios Dosing Calculator for peptide concentration conversions (note: topical cosmetic percentages are not pharmaceutical doses)

Side Effects & Risks

Palmitoyl Dipeptide-6 has a clean safety profile consistent with the broader palmitoyl-lipopeptide cosmetic class. The Cosmetic Ingredient Review Expert Panel has assessed palmitoyl oligopeptides as safe as used in cosmetic formulations. Specific risks to be aware of:

• Contact sensitization (rare) — Any cosmetic peptide can in principle trigger delayed-type hypersensitivity, particularly in individuals with pre-existing atopic dermatitis or fragrance/preservative polysensitization. Post-market reports for Palmitoyl Dipeptide-6 are rare and typically confounded by other formulation ingredients (preservatives, fragrances, emulsifier systems). Patch testing is prudent for sensitive-skin consumers before full-face use.
• Palmitoyl comedogenicity (formulation-dependent) — Palmitic-acid-containing ingredients can contribute to comedogenicity in acne-prone skin at high concentrations or in occlusive vehicles. At cosmetic-typical inclusion levels (1–4%) in a well-balanced formulation, Palmitoyl Dipeptide-6 is not considered notably comedogenic, but individuals with clinically active acne or severe seborrhea should test a small area first.
• Irritation potential (low) — The pal-VW structure is not inherently irritating. Reported irritation in patch testing is almost always attributable to formulation adjuncts (solvents, preservatives, emulsifiers) rather than to the peptide itself.
• Photosensitivity (not reported) — No meaningful photosensitizing activity reported for Palmitoyl Dipeptide-6. It is not a photosensitizer, and it does not require photoprotection distinct from normal daytime SPF recommendations.
• Pregnancy and lactation — As a topical cosmetic peptide with minimal systemic absorption (the palmitoyl-lipid anchor keeps it in the stratum corneum and viable epidermis rather than transiting into the systemic circulation), Palmitoyl Dipeptide-6 is generally considered low-risk during pregnancy and lactation. However, pregnant or nursing individuals should consult their obstetrician before adopting any new cosmetic product, and supplier-level safety dossiers generally caution that comprehensive human pregnancy data are absent.
• Pediatric use — Cosmetic signal peptides including Palmitoyl Dipeptide-6 are not indicated for pediatric use. No safety or efficacy data in children.
• No systemic safety data — Palmitoyl Dipeptide-6 has not been evaluated for oral or parenteral safety. It should not be ingested, inhaled as an aerosol, or injected. It is a topical cosmetic ingredient only.
• Drug interactions (topical) — No clinically meaningful interactions reported. Can be layered with retinoids, vitamin C, niacinamide, alpha-hydroxy acids, and standard sunscreen actives in most formulation contexts. Sequencing guidance (e.g., applying retinol at night and Palmitoyl Dipeptide-6 in the morning) is formulation-specific and driven by pH and antioxidant considerations rather than by biological incompatibility.
• Self-assembly behavior — Palmitoyl lipopeptides can self-assemble into micelles or nanotapes at concentrations above their critical aggregation concentration. In formulation this can produce slight turbidity or gel-like behavior; neither represents a safety concern, but formulators should account for phase behavior when designing transparent serums.
• Tryptophan oxidation — The tryptophan residue in pal-VW is oxidation-sensitive. Oxidized tryptophan can produce kynurenine-pathway breakdown products whose safety in topical formulations has not been comprehensively characterized. Adequate antioxidant protection and a well-controlled manufacturing oxygen environment minimize this risk; consumers should not use products whose color has shifted dramatically toward yellow-brown from original pale-straw.
• Comparison to botulinum toxin — Palmitoyl Dipeptide-6 is not a neurotoxin, not a presynaptic inhibitor, and not mechanistically similar to botulinum toxin. Marketing that frames the ingredient as "botox alternative" is not mechanistically accurate; that framing belongs to Argireline-class materials (acetyl hexapeptide-8), not to Palmitoyl Dipeptide-6.

Bloodwork & Monitoring

Palmitoyl Dipeptide-6 is a topical cosmetic ingredient. There is no bloodwork, pharmacokinetic monitoring, or laboratory surveillance indicated for its cosmetic use. The palmitoyl-lipid anchor is specifically designed to increase stratum-corneum residence time and viable epidermis penetration while minimizing systemic transit — which means there is essentially no systemic pharmacokinetic compartment to monitor.

• No routine bloodwork indicated — Unlike parenteral peptides (GLP-1 agonists, growth-hormone secretagogues, BPC-157, GHK-Cu systemic use), topical cosmetic peptides at typical inclusion levels do not produce measurable systemic exposure and do not require laboratory monitoring.
• No hepatic monitoring indicated — Topical cosmetic peptides do not traverse first-pass metabolism or produce measurable hepatic exposure at cosmetic use levels.
• No renal monitoring indicated — Palmitoyl Dipeptide-6 is not renally cleared in any clinically meaningful quantity from topical use.
• Patch test for sensitive skin — The only "monitoring" recommended for the general consumer is a 48-hour patch test on the inner forearm before full-face application in individuals with sensitive skin, known atopic dermatitis, or a history of cosmetic-product allergic contact dermatitis. A positive patch test (redness, itching, papules at 48 hours) is an indication not to use the product, not to obtain further laboratory workup.
• Photographic baseline for efficacy tracking — Consumers interested in tracking whether a Palmitoyl Dipeptide-6-containing product is working for them should take standardized baseline photographs (same lighting, same camera, same angle, no makeup) at week 0 and re-photograph at weeks 4, 8, and 12. Cosmetic signal-peptide effects, if present, are modest and slow; single-before-after comparisons are notoriously unreliable. The palmitoyl-lipopeptide class is a compounding contributor to a multi-year skincare routine, not a before-and-after transformation.
• No concern for athletes — Palmitoyl Dipeptide-6 is not on the WADA Prohibited List and topical cosmetic use presents no doping-monitoring concern.

Commonly Stacked With

In a cosmetic formulation context, "stacking" refers to combining complementary actives within a finished product or within a daily topical routine. Palmitoyl Dipeptide-6 is most commonly paired with other signal peptides, neuromuscular-affecting peptides, carrier peptides, and retinoids in firming and anti-aging routines.

→ Check peptide compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Palmitoyl Dipeptide-6 often also look at these:

Next Steps

Key References

1. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-160. PMID: 18492182. (The foundational 93-woman split-face RCT of pal-KTTKS 3 ppm — the strongest finished-product evidence in the palmitoyl-lipopeptide cosmetic class and the category anchor for lipidated signal-peptide claims.)
2. Katayama K, Armendariz-Borunda J, Raghow R, Kang AH, Seyer JM. A pentapeptide from type I procollagen promotes extracellular matrix production. J Biol Chem. 1993;268(14):9941-9944. PMID: 8486721. (Founding in-vitro demonstration that the KTTKS pentapeptide stimulates type I collagen, type III collagen, and fibronectin production in fibroblast cultures — the biochemical anchor for the "matrikine" cosmetic-peptide framework.)
3. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22(3):207-218. PMID: 18503476. (Sederma's foundational review establishing the cosmetic-lipopeptide strategic framework — palmitoylation for stratum-corneum delivery, matrikine concept, chemotaxis and anti-stinging effects. Reference text for supplier-dossier vocabulary.)
4. Abu Samah NH, Heard CM. Topically applied KTTKS: a review. Int J Cosmet Sci. 2011;33(6):483-490. PMID: 21535443. (Comprehensive academic review of KTTKS and its major derivatives including palmitoylated forms. Addresses physicochemical properties, theoretical skin permeation, and evidence appraisal.)
5. Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. PMID: 18045359. (Dermatology-review classification of cosmetic peptides into signal, neurotransmitter-affecting, and carrier categories. Notes the limited efficacy-testing rigor of the field as a whole.)
6. Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics (MDPI). 2017;4(2):16. DOI: 10.3390/cosmetics4020016. (Peer-reviewed open-access survey of cosmeceutical peptides against intrinsic and extrinsic aging — places palmitoyl lipopeptides in the signal-peptide category and summarizes class-level evidence.)
7. Castelletto V, Hamley IW, Whitehouse C, Matts PJ, Osborne R, Baker ES. Self-Assembly of Palmitoyl Lipopeptides Used in Skin Care Products. Langmuir. 2013;29(29):9149-9155. DOI: 10.1021/la401771j. (Biophysical characterization of pal-KTTKS, pal-GHK, and pal-KT self-assembly — establishes that palmitoyl cosmetic lipopeptides form β-sheet nanotape and micellar structures above critical aggregation concentration, with implications for in-vehicle behavior.)
8. Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. DOI: 10.1046/j.1467-2494.2002.00153.x. (Founding mechanism paper for acetyl hexapeptide-8 — cited here as a methodological comparison for a cosmetic-peptide active with a defined molecular mechanism, to contrast with Palmitoyl Dipeptide-6's thinner mechanistic record.)
9. Cosmetic Ingredient Review Expert Panel. Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics. CIR. 2012. (Class-level cosmetic-ingredient safety assessment covering palmitoyl oligopeptides including palmitoyl dipeptide class entries. Available via cir-safety.org. Establishes the safety floor for the ingredient family.)
10. Wakao T, Oyama H, Hara D, Nakaseko T, Kimura S, Wakabayashi H. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. J Rehabil Med. 2012;44(10):888-891. PMID: 23146065. (Small pilot demonstrating a cosmetic peptide active's topical clinical utility — tangentially relevant category context for topical-peptide clinical-evidence expectations.)
11. Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci. 2009;31(5):327-345. DOI: 10.1111/j.1468-2494.2009.00490.x. (Review of topical peptide cosmetics with evidence-rating discussion across the signal / neurotransmitter / carrier peptide categories. Useful framing for evaluating Palmitoyl Dipeptide-6 against class peers.)
12. Proksch E, Segger D, Degwert J, Schunck M, Zague V, Oesser S. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study. Skin Pharmacol Physiol. 2014;27(1):47-55. PMID: 23949208. (Oral collagen-peptide RCT cited here to clarify that oral collagen-peptide literature is not transferable to topical lipopeptide marketing — a common conflation.)
13. Fields K, Falla TJ, Rodan K, Bush L. Bioactive peptides: signaling the future. J Cosmet Dermatol. 2009;8(1):8-13. DOI: 10.1111/j.1473-2165.2009.00416.x. (Review of bioactive peptides in dermatology, including discussion of signal peptides and palmitoyl lipopeptides as the leading topical class.)
14. Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Dermatol Clin. 2009;27(4):401-416. DOI: 10.1016/j.det.2009.08.006. (Dermatology-clinic practical review covering cosmeceutical peptide categories and evidence appraisal for a clinician audience.)
15. Draelos ZD. Cosmeceuticals: undefined, unclassified, and unregulated. Clin Dermatol. 2009;27(5):431-434. DOI: 10.1016/j.clindermatol.2009.05.005. (Editorial framing of the cosmeceutical regulatory category — directly relevant to Palmitoyl Dipeptide-6's ambiguous regulatory classification and evidence expectations.)
16. Zhang L, Falla TJ. Cosmeceuticals and peptides. Clin Dermatol. 2009;27(5):485-494. DOI: 10.1016/j.clindermatol.2009.05.013. (Review specifically on cosmetic peptides from a dermatology-clinic perspective, addressing the signal-peptide class including palmitoylated variants.)
17. Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. DOI: 10.4103/0378-6323.186500. (Narrative review of topical peptide cosmeceuticals including palmitoyl lipopeptides; evaluates evidence and regulatory framework for the category.)
18. Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020;8:572923. DOI: 10.3389/fchem.2020.572923. (Contemporary review of cosmeceutical peptide chemistry, delivery, and regulatory frameworks. Useful for placing Palmitoyl Dipeptide-6 within the modern cosmetic-peptide landscape.)